65271-80-9
基本信息
米托蒽醌
米托恩醌
MITOXANTRONE
1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedi
5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-anthraquinon
5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
9,10-anthracenedione,1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)a
dihydroxyanthraquinone
mitoxanthrone
nsc279836
MitoxantroneBase
Mitoxantrone Hcl 70476-82-3 / Base
PharmasubstanceEP4
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
NSC-27983
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-
1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthrace nedimitoxantrone
MITOXANTRONUM AND THE INTERMEDIATES
Mitoxantrone (base and/or unspecified salts)
MITOXANTRONUM
1,4-Dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethylamino]-9,10-anthraquinone
物理化学性质
| 外观性状 | 蓝黑色结晶。熔点203-205℃。略溶于水，微溶于乙醇，不溶于氯仿和丙酮。无臭，易吸潮 |
| 熔点 | 170-1740C |
| 沸点 | 554.47°C (rough estimate) |
| 密度 | 1.3049 (rough estimate) |
| 折射率 | 1.6500 (estimate) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | DMSO（少量）、甲醇（少量）、水（少量） |
| 酸度系数(pKa) | pKa 5.99 (Uncertain);8.13 (Uncertain) |
| 形态 | 固体 |
| 颜色 | 深蓝色到黑色 |
| CAS 数据库 | 65271-80-9(CAS DataBase Reference) |
| (IARC)致癌物分类 | 2B (Vol. 76) 2000 |
安全数据
| 危险性符号(GHS) |   GHS08,GHS09 |
| 警示词 | 警告 |
| 危险性描述 | H351-H411 |
| 防范说明 | P201-P202-P281-P308+P313-P405-P501 |
| 危险品标志 | T |
| 危险类别码 | R46-R61 |
| 安全说明 | S53-S36/37/39-S45 |
| WGK Germany | 3 |
| RTECS号 | CB5748500 |
| 海关编码 | 2922.50.2500 |
应用领域
米托蒽醌价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 50mg | 515元 |
| 2024/01/25 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 10mM * 1mLin DMSO | 567元 |
| 2024/01/25 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 100mg | 744元 |
常见问题列表
|
PKC 8.5 μM (IC 50 ) |
Topoisomerase II
|
Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 μg/mL) induces a decrease in cell viability. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC 50 values of 18 and 196 nM, respectively.
Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produces a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also shows effective antitumor activities and produces a 60% and a 45% ILS, respectively..